COVID

MP Gallant Gives Red Light to using Military Soldiers as COVID-19 Vaccine Test Subjects

Canadian military members should not be used as test subjects for the Ad5-nCoV vaccine given the green light for use in members of the Chinese military.

News that the vaccine developed under the supervision of the Chinese military has already been approved for human testing in Canada, raises the concern that Canadian Military members will be ordered by the Trudeau government to be human guinea pigs for the new vaccine. The vaccine was approved for human testing before all phases of testing are complete.

The vaccine was developed with taxpayer funding.

As the MP for the last home of the proud Canadian Airborne Regiment that was scapegoated by former PM Jean Chretien during the infamous “decade of darkness” era of Liberal military cutbacks, veterans in my Riding, have bad memories.

During the Canadian Airborne Regiment’s final deployment to Somalia, soldiers were administered an experimental treatment, mefloquine, which is used as an anti-malaria drug. Its use is now the subject of a lawsuit that was filed against the Canadian government in the spring of last year. Soldiers who were administered the drug report side-effects today more than 25 years after they were inoculated.

Coincidentally, other anti-malaria drugs are being tested to see if they can prevent infection with COVID-19.

In China the Ad5-nCoV COVID-19 vaccine has been approved for use on members of the Chinese military only. China has declined to disclose whether vaccination will be mandatory or optional.

Unfortunately Canada has a history of using soldiers as test subjects dating back to the First World War. At the very least, Parliament must be recalled. A full examination of the facts through democratic debate is needed before any soldier is coerced into testing a vaccine developed with the Chinese military.

Please, join me in standing up for our serving members of the Canadian Armed Forces in raising concerns with the Minister

No comments yet.

Leave a Reply